{
    "nct_id": "NCT05462106",
    "title": "A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)",
    "status": "RECRUITING",
    "last_update_time": "2025-06-11",
    "description_brief": "The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.",
    "description_detailed": "This phase 1b/2 study will be in 2 parts. Study Part 1 will involve subjects with prodromal Alzheimer's disease. Study Part 2 will involve subjects with Down syndrome.",
    "phase": [
        "PHASE1",
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "ACI-24.060 (ACI\u201124 anti-amyloid\u2011\u03b2 vaccine; liposome\u2011based, SupraAntigen\u00ae platform)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests ACI-24.060, an active vaccine designed to elicit polyclonal anti\u2011amyloid\u2011\u03b2 antibodies to engage and reduce pathological A\u03b2 species (disease\u2011modifying intent), which makes it a biologic targeting Alzheimer\u2019s pathology. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act (extracted details): ACI\u201124.060 is described as a liposome\u2011based anti\u2011A\u03b2 vaccine (SupraAntigen\u00ae platform) that induces antibodies against oligomeric and pyroglutamate\u2011A\u03b2 species; the ABATE trial is randomized, double\u2011blind, placebo\u2011controlled in prodromal AD and adults with Down syndrome. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Act (supporting evidence): Prior Phase 1b data in adults with Down syndrome showed safety/tolerability and evidence of immunogenicity for the ACI\u201124 program; AC Immune\u2019s press releases and coverage note the vaccine\u2019s mechanism and ongoing mid\u2011stage ABATE study. \ue200cite\ue202turn0search3\ue202turn0news12\ue201",
        "Reflect: Classification as a \"disease\u2011targeted biologic\" is appropriate because ACI\u201124.060 is an immunotherapy (vaccine) specifically targeting Alzheimer\u2019s pathology (amyloid\u2011\u03b2). It is not a small molecule, a symptomatic cognitive enhancer, nor an agent aimed at neuropsychiatric symptom management, so other categories do not fit. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web search results (key sources): AC Immune press release on ABATE and ACI\u201124.060 (Jan 26, 2023). \ue200cite\ue202turn0search0\ue201; PubMed/PMC report on ACI\u201124 vaccine safety/tolerability in adults with Down syndrome. \ue200cite\ue202turn0search3\ue202turn0search1\ue201; AC Immune news on trial centers and ACI\u201124.060 description. \ue200cite\ue202turn0search4\ue201; Financial Times coverage of Takeda licensing/partnership relating to ACI\u201124.060. \ue200cite\ue202turn0news12\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational agent ACI-24.060 is an active (liposome\u2011based, SupraAntigen\u00ae) vaccine designed to elicit polyclonal anti\u2013amyloid\u2011\u03b2 antibodies that bind pathological A\u03b2 species (oligomeric and pyroglutamate\u2011A\u03b2) with the goal of reducing/clearing A\u03b2 and modifying disease course, so the biological focus is explicitly amyloid\u2011\u03b2. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Act: Extracted details from the trial description and public sources \u2014 ACI\u201124.060 is an anti\u2011A\u03b2 active immunotherapy (vaccine) using AC Immune\u2019s SupraAntigen\u00ae liposome platform, shown safe/tolerable and immunogenic in prior Phase 1b DS data and being tested in the randomized, placebo\u2011controlled Phase 1b/2 ABATE study in prodromal AD and adults with Down syndrome. These items point to a targeted anti\u2011amyloid therapeutic mechanism (disease\u2011modifying intent). \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Classification as A) Amyloid beta is the best fit \u2014 the intervention directly targets amyloid\u2011\u03b2 pathology (not tau, inflammation, synaptic modulators, metabolic or diagnostic procedures), and the trial documents and press releases consistently describe ACI\u201124.060 as an anti\u2011A\u03b2 vaccine with PET/plaque reduction as a pharmacodynamic endpoint. No evidence in the description indicates multiple distinct CADRO targets, so R) Multi\u2011target is not appropriate. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Web search results (key sources cited above):",
        "- PubMed: \"Safety, Tolerability, and Immunogenicity of the ACI\u201124 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial\" (Phase 1b safety/immunogenicity data). \ue200cite\ue202turn0search0\ue201",
        "- AC Immune press release: \"ACI\u201124.060 Anti\u2011Amyloid Beta Vaccine for Alzheimer\u2019s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial\" (Jan 26, 2023). \ue200cite\ue202turn0search1\ue201",
        "- AC Immune info on ACI\u201124.060 / SupraAntigen\u00ae platform (asset description and mechanism). \ue200cite\ue202turn0search2\ue201",
        "- AC Immune: FDA Fast Track designation for ACI\u201124.060 (describes anti\u2011Abeta active immunotherapy and trial aims). \ue200cite\ue202turn0search4\ue201",
        "- Takeda press release: exclusive option/license agreement describing ACI\u201124.060 as an anti\u2011Abeta active immunotherapy evaluated in the ABATE trial. \ue200cite\ue202turn0search5\ue201"
    ]
}